Please select the option that best describes you:

What is your approach to differentiating and managing DMARD-induced nodulosis (induced by methotrexate or leflunomide for example) from "de novo" RA nodules in seropositive RA patients?   



Answer from: at Academic Institution
Comments
at The Center for Rheumatology
@Simon, Agree with your descriptions, particularly...
at Uniformed Services University of the Health Sciences (USUHS)
@Simon M. Helfgott: That is a very nice, practical...
at UTMB Health
Years ago, I had an older patient with RA who deve...
Sign in or Register to read more